Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8697011 | 0.88 | CA14 (0.37) | CA14CA1HDAC6CA12HDAC1 | |
| SCHEMBL12342815 | 0.84 | CA14 (0.53) | CA14DGAT1CA1HDAC6CA12 | |
| SCHEMBL30380554 | 0.83 | CA14 (0.36) | CA14DGAT1CA1HDAC6CA12 | |
| SCHEMBL30380292 | 0.83 | CA14 (0.36) | CA14DGAT1CA1HDAC6CA12 | |
| SCHEMBL30381232 | 0.83 | CA14 (0.36) | CA14DGAT1CA1HDAC6CA12 | |
| SCHEMBL30380396 | 0.83 | CA14 (0.36) | CA14DGAT1CA1HDAC6CA12 | |
| SCHEMBL30380680 | 0.83 | CA14 (0.36) | CA14DGAT1CA1HDAC6CA12 | |
| SCHEMBL24401196 | 0.82 | CA14 (0.41) | CA14DGAT1CA1HDAC6CA12 | |
| SCHEMBL381086 | 0.82 | CA14 (0.41) | CA14DGAT1CA1HDAC6CA12 | |
| SCHEMBL17160806 | 0.81 | CA14 (0.40) | CA14DGAT1CA1HDAC6CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683394-B1 | ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS | SIGNATURE THERAPEUTICS INC (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10028945-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028945-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028945-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | 3I, LP | 2017-05-04 | — | — | US | disclosed |
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | 3I, LP | 2017-05-04 | — | — | US | disclosed |
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | 3I, LP | 2017-05-04 | — | — | US | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20120178773-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | 3I, LP | 2012-07-12 | — | — | US | disclosed |
| US-20120178772-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | 3I, LP | 2012-07-12 | — | — | US | disclosed |
| US-20120178773-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | 3I, LP | 2012-07-12 | — | — | US | disclosed |
| US-20120178772-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | 3I, LP | 2012-07-12 | — | — | US | disclosed |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| WO-2011031350-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | ACHE, CYP2C18, CYP2C9 | CA14 506/4885DGAT1 2681/4885CA1 402/4885 |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PEPD, TMPRSS15, ADAM17 | CA14 482/4885DGAT1 3005/4885CA1 232/4885 |
| US-20120178773-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | OPRK1, CYP3A7, OPRD1 | CA14 988/4885DGAT1 3521/4885CA1 120/4885 |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | ACHE, OPRM1, DNPEP | CA14 816/4885DGAT1 2646/4885CA1 348/4885 |
| US-20120178772-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | OPRK1, KDM8, ADAM8 | CA14 674/4885DGAT1 2715/4885CA1 92/4885 |
| US-10028945-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | ACHE, CYP2C18, CYP2C9 | CA14 506/4885DGAT1 2681/4885CA1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.